{"nctId":"NCT01503515","briefTitle":"Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant","startDateStruct":{"date":"2013-03-21","type":"ACTUAL"},"conditions":["Fungal Infection","Hematopoietic and Lymphoid Cell Neoplasm"],"count":292,"armGroups":[{"label":"Arm I (caspofungin acetate)","type":"EXPERIMENTAL","interventionNames":["Drug: Caspofungin Acetate","Other: Laboratory Biomarker Analysis"]},{"label":"Arm II (fluconazole or voriconazole)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fluconazole","Other: Laboratory Biomarker Analysis","Drug: Voriconazole"]}],"interventions":[{"name":"Caspofungin Acetate","otherNames":["Cancidas"]},{"name":"Fluconazole","otherNames":["Diflucan"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Voriconazole","otherNames":["Vfend"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age\n\n  * For centers that will use fluconazole as the antifungal comparator:\n\n    * Age \\>= 3 months and \\< 21 years\n  * For centers that will use voriconazole as the antifungal comparator:\n\n    * Age \\>= 2 years and \\< 21 years\n* The patient must be undergoing allogeneic HCT from any donor (including matched related) with any stem cell source for any underlying condition\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients \\> 16 years of age and Lansky for patients =\\< 16 years of age\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \\>= 70 mL/min/1.73 m\\^2 OR a serum creatinine based on age/gender as follows:\n\n  * 0.4 mg/dL (1 month to \\< 6 months of age)\n  * 0.5 mg/dL (6 months to \\< 1 year of age)\n  * 0.6 mg/dL (1 to \\< 2 years of age)\n  * 0.8 mg/dL (2 to \\< 6 years of age)\n  * 1.0 mg/dL (6 to \\< 10 years of age)\n  * 1.2 mg/dL (10 to \\< 13 years of age)\n  * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \\< 16 years of age)\n  * 1.7 mg/dL (male) or 1.4 mg/dL (female) (\\>= 16 years of age)\n* Total bilirubin \\< 2.5 mg/dL unless the increase in bilirubin is attributable to Gilbert's syndrome\n* Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \\[AST\\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \\[ALT\\]) \\< 5 x upper limit of normal (ULN) for age\n* All patients and/or their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\n\nExclusion Criteria:\n\n* Within 90 days of enrollment:\n\n  * Patients with a proven or probable invasive mold infection are not eligible\n  * Patients with an incompletely treated invasive yeast infection are not eligible\n  * Patients with an elevated galactomannan level (\\>= 0.5 index) within 30 days prior to time of enrollment (if performed) must have a full evaluation for invasive aspergillosis (including a negative chest computed tomography \\[CT\\] scan) during that time period to be eligible for enrollment\n* Patients receiving treatment for an IFI are not eligible\n* Patients with a history of echinocandin or azole hypersensitivity are not eligible\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"20 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections (IFI)","description":"Kaplan-Meier curves will be used to estimate the 42- day-cumulative incidence of proven/probable IFI following allogeneic HCT for patients randomized to the 2 arms. Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"100-day-cumulative Incidence of Proven or Probable IFI","description":"Kaplan-Meier curves will be used to estimate the 100- day-cumulative incidence of proven/probable IFI following allogeneic HCT for patients randomized to the 2 arms. Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG).","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Fungal-free-survival","description":"Defined as time to death or proven/probable IFI during the first 42 days following allogeneic HCT.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence of Overall Clinical GVHD Grades III and IV","description":"The percentage distribution of overall clinical grades III and IV will be estimated for each arm.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence of Overall Clinical GVHD Grades II to IV","description":"The percentage distribution of overall clinical grades II and IV will be estimated for each arm.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Fungal-free-survival","description":"Defined as time to death or proven/probable IFI during the first 100 days following allogeneic HCT.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity of Beta-D Glucan Assay for the Diagnosis of IFI Using Fungitell Assay","description":"Sensitivity of the beta-D glucan assay will be determined using standard formulas and EORTC/MSG criteria as the gold standard.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Specificity of Beta-D Glucan Assay for the Diagnosis of IFI Using Fungitell Assay","description":"Specificity of the beta-D glucan assay will be determined using standard formulas and EORTC/MSG criteria as the gold standard.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Positive Predictive Value of Beta-D Glucan Assay for the Diagnosis of IFI Using Fungitell Assay","description":"Positive predictive value of the beta-D glucan assay will be determined using standard formulas and EORTC/MSG criteria as the gold standard.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Negative Predictive Value of Beta-D Glucan Assay for the Diagnosis of IFI Using Fungitell Assay","description":"Negative predictive value of the beta-D glucan assay will be determined using standard formulas and EORTC/MSG criteria as the gold standard.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":144},"commonTop":["Respiratory failure","Alanine aminotransferase increased","Aspartate aminotransferase increased","Acute kidney injury","Sepsis"]}}}